{
    "clinical_study": {
        "@rank": "95645", 
        "acronym": "CIBLE", 
        "arm_group": [
            {
                "arm_group_label": "AVAPS", 
                "arm_group_type": "Active Comparator", 
                "description": "AVAPS mode(BIPAP-A30-PHILIPS-RESPIRONICS)1 night"
            }, 
            {
                "arm_group_label": "IVAPS", 
                "arm_group_type": "Active Comparator", 
                "description": "IVAPS mode(STELAR 150-RESMED)1 night"
            }
        ], 
        "brief_summary": {
            "textblock": "Patients with OHS are efficiently managed with long term home-based nocturnal noninvasive\n      positive pressure ventilation (NIPPV). Several NIPPV devices offer the feature of\n      automatically adjusting pressure support (and/or respiratory back-up rate) on the basis of a\n      pre-determined \"ideal tidal volume\" or \"ideal ventilation\".  However algorithms used to\n      achieve these ideal targets are different among different commercialized devices and the\n      relative efficacy from an algorithm compared to another remains unknown. The main objective\n      is this study is to compare two commercialized NIPPV that have this option"
        }, 
        "brief_title": "Target Volume in Noninvasive Positive Pressure Ventilation", 
        "completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "condition": "Obesity Hypoventilation Syndrome", 
        "condition_browse": {
            "mesh_term": [
                "Obesity", 
                "Obesity Hypoventilation Syndrome", 
                "Hypoventilation", 
                "Respiratory Insufficiency"
            ]
        }, 
        "detailed_description": {
            "textblock": "RESMED Stellar-150 (IVAPS mode)versus PHILIPS-RESPIRONICS A30 (AVAPS-mode)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient with Obesity hypoventilation Syndrome (BMI\u2265 30 kg/m2 and diurnal PaCO2 \u2265\n             45mmHg at diagnosis after exclusion of others causes of hypoventilation)\n\n          -  18 to 75 years old\n\n          -  In stable state but treated by nocturnal NIPPV for more than 3 months and adherent to\n             NIPPV (above 4h/night).\n\n        Exclusion Criteria:\n\n          -  patient treated with additional long term Oxygen therapy\n\n          -  Patient previously treated by AVAPS mode or IVAPS mode"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "12", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "December 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01748656", 
            "org_study_id": "12-AGIR-02"
        }, 
        "intervention": [
            {
                "arm_group_label": "AVAPS", 
                "description": "IVAPS mode (RESMED Stelar 150) during 1 night", 
                "intervention_name": "IVAPS", 
                "intervention_type": "Device"
            }, 
            {
                "arm_group_label": "IVAPS", 
                "description": "AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night", 
                "intervention_name": "AVAPS", 
                "intervention_type": "Device"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Noninvasive ventilation", 
            "Obesity Hypoventilation Syndrome"
        ], 
        "lastchanged_date": "March 13, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Grenoble", 
                    "country": "France", 
                    "zip": "38900"
                }, 
                "name": "Sleep Laboratory, Grenoble Univeristy Hospital"
            }
        }, 
        "location_countries": {
            "country": "France"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Two Noninvasive Positive Pressure Ventilation Devices Using Target Volume Modes in Obesity Hypoventilation Syndrome (OHS): A Pilot Randomized Crossover Controlled Trial", 
        "overall_official": {
            "affiliation": "CHU Grenoble France", 
            "last_name": "Jean Louis Pepin, MD PHD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "France: Committee for the Protection of Personnes", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "transcutaneous CO2 pressure is measured overnight. It is a reliable estimation of arterial PaCO2 to monitor nocturnal ventilation in adults with chronic respiratory failure.", 
            "measure": "Mean Nocturnal transcutaneous CO2 pressure (Mean nocturnal PtCO2)", 
            "safety_issue": "No", 
            "time_frame": "1 night"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01748656"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Mean transcutaneous CO2 pressure during REM Sleep", 
                "safety_issue": "No", 
                "time_frame": "1 Night"
            }, 
            {
                "measure": "Mean nocturnal SpO2", 
                "safety_issue": "No", 
                "time_frame": "1 night"
            }, 
            {
                "measure": "Awake arterial PaCO2 after 1 hour of NIPPV withdrawal", 
                "safety_issue": "No", 
                "time_frame": "After 1 night"
            }, 
            {
                "measure": "Micro-arousals/hour of sleep", 
                "safety_issue": "No", 
                "time_frame": "1 night"
            }, 
            {
                "measure": "Sleep Quality assess by Visual analogic scale (100mm)", 
                "safety_issue": "No", 
                "time_frame": "1 night"
            }, 
            {
                "measure": "Respiratory residual events detected by NIPPV built-in softwares", 
                "safety_issue": "No", 
                "time_frame": "1 Night"
            }
        ], 
        "source": "AGIR \u00e0 Dom", 
        "sponsors": {
            "collaborator": {
                "agency": "ResMed", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "AGIR \u00e0 Dom", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2012"
    }
}